Concepedia

Author

Ofra Novoplansky

Ben-Gurion University of the NegevORCID

Also Known As

Ofra Novoplansky, Ofra Z. Novoplansky

24

Publications

429

Citations

10

H-Index

20

Concepts

All Affiliations

Ben-Gurion University of the NegevSoroka Medical CenterMemorial Sloan Kettering Cancer CenterTianjin Medical UniversityGerman Cancer Research Center
ON

About

Ofra Novoplansky is an author at Ben-Gurion University of the Negev specializing in cell biology, medicine, and natural sciences.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

2

2

74

2

Cell Biology

2

2

74

3

Natural Sciences

1

1

38

4

Molecular Biology

1

1

38

5

Pathology

1

1

36

Ofra Novoplansky

×

8

Publications

315

Citations

8

H-Index

YearCitations

MEK1/2 inhibition transiently alters the tumor immune microenvironment to enhance immunotherapy efficacy against head and neck cancer

Manu Prasad, Jonathan Zorea, Sankar Jagadeeshan,

Journal for ImmunoTherapy of Cancer

2022

66

TGF-Beta-Activated Cancer-Associated Fibroblasts Limit Cetuximab Efficacy in Preclinical Models of Head and Neck Cancer

Ksenia M. Yegodayev, Ofra Novoplansky, Artemiy Golden,

Cancers

2020

54

Unraveling the hidden role of a uORF-encoded peptide as a kinase inhibitor of PKCs

Divya Ram Jayaram, Sigal A. Frost, Chanan M Argov,

Proceedings of the National Academy of Sciences

2021

51

Ubiquitin Accumulation on Disease Associated Protein Aggregates Is Correlated with Nuclear Ubiquitin Depletion, Histone De-Ubiquitination and Impaired DNA Damage Response

Adi Ben Yehuda, Marwa Risheq, Ofra Novoplansky,

PLoS ONE

2017

38

EGFR overexpression increases radiotherapy response in HPV-positive head and neck cancer through inhibition of DNA damage repair and HPV E6 downregulation

Elham Alsahafi, Selvam Thavaraj, Nazanin Namazi Sarvestani,

Cancer Letters

2020

36

MET activation confers resistance to cetuximab, and prevents HER2 and HER3 upregulation in head and neck cancer

Ofra Novoplansky, Matthew G. Fury, Manu Prasad,

International Journal of Cancer

2019

30

Activation of the <scp>EGFR</scp> / <scp>PI3K</scp> / <scp>AKT</scp> pathway limits the efficacy of trametinib treatment in head and neck cancer

Ofra Novoplansky, Avital Beeri Shnerb, Divyasree Marripati,

Molecular Oncology

2023

28

Developing a dual VEGF/PDL1 inhibitor based on high-affinity scFv heterodimers as an anti-cancer therapeutic strategy

Noam Tzuri, Ksenia M. Yegodayev, Ofra Novoplansky,

Scientific Reports

2023

12

Page 1